Display options
Cite
Baruah P, Das A, Paul D, et al. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021;4(1):193-205doi: 10.1021/acsptsci.0c00168.
Baruah, P., Das, A., Paul, D., Chakrabarty, S., Aguan, K., & Mitra, S. (2021). Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS pharmacology & translational science, 4(1), 193-205. https://doi.org/10.1021/acsptsci.0c00168
Baruah, Prayasee, et al. "Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease." ACS pharmacology & translational science vol. 4,1 (2021): 193-205. doi: https://doi.org/10.1021/acsptsci.0c00168
Baruah P, Das A, Paul D, Chakrabarty S, Aguan K, Mitra S. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12. PMID: 33615172; PMCID: PMC7887854.
Copy Download .nbib Format: NLM
Share it on

ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12.

Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease.

ACS pharmacology & translational science

Prayasee Baruah, Abhinandan Das, Debojit Paul, Suman Chakrabarty, Kripamoy Aguan, Sivaprasad Mitra

Affiliations

  1. Centre for Advanced Studies in Chemistry and Department of Biotechnology & Bioinformatics, North-Eastern Hill University, Shillong 793022, India.
  2. Department of Chemical, Biological & Macromolecular Sciences, S. N. Bose National Centre for Basic Sciences, Salt Lake City, Kolkata 700106, India.
  3. Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, India.

PMID: 33615172 PMCID: PMC7887854 DOI: 10.1021/acsptsci.0c00168

Abstract

Contemporary literature documents extensive research on common causative mechanisms, pathogenic pathways and dual effective remedies for Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM). Tolbutamide (TBM), chlorpropamide (CPM), and glyburide (GLY) are three sulfonylurea antidiabetic drugs of different generations. All these drugs were found to exhibit moderate to strong inhibitory efficiency on the neurotransmitter degrading enzyme acetylcholinesterase (AChE) with GLY (IC

© 2021 American Chemical Society.

Conflict of interest statement

The authors declare no competing financial interest.

References

  1. Neurology. 2008 Sep 30;71(14):1065-71 - PubMed
  2. Neurol India. 2000 Dec;48(4):308-13 - PubMed
  3. Anaesthesia. 2009 Mar;64 Suppl 1:1-9 - PubMed
  4. Alzheimers Dement. 2017 Jan;13(1):1-7 - PubMed
  5. Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:23-33 - PubMed
  6. Am J Epidemiol. 2001 Oct 1;154(7):635-41 - PubMed
  7. J Alzheimers Dis. 2005 Dec;8(3):247-68 - PubMed
  8. Biochem Pharmacol. 1961 Jul;7:88-95 - PubMed
  9. Biochem Biophys Res Commun. 2011 Jan 28;404(4):935-40 - PubMed
  10. Ther Adv Neurol Disord. 2013 Jan;6(1):19-33 - PubMed
  11. Mayo Clin Proc. 2009;84(1):28-33 - PubMed
  12. Br Med J. 1978 Jan 21;1(6106):142-4 - PubMed
  13. PLoS One. 2015 Apr 13;10(4):e0121092 - PubMed
  14. Behav Brain Res. 2008 Jun 3;189(2):381-6 - PubMed
  15. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):447-51 - PubMed
  16. J R Soc Interface. 2015 Jan 6;12(102):20140891 - PubMed
  17. Neurobiol Aging. 2006 Feb;27(2):190-8 - PubMed
  18. Neurochem Res. 2016 Jun;41(6):1475-82 - PubMed
  19. J Comput Chem. 2010 Mar;31(4):671-90 - PubMed
  20. Sci Rep. 2017 Jun 12;7(1):3219 - PubMed
  21. J Med Chem. 2006 Oct 19;49(21):6177-96 - PubMed
  22. ACS Nano. 2017 Mar 28;11(3):2313-2381 - PubMed
  23. J Biomol Struct Dyn. 2015;33(5):1107-25 - PubMed
  24. Arch Med Sci. 2015 Aug 12;11(4):840-8 - PubMed
  25. Chem Rev. 2009 Sep;109(9):4025-53 - PubMed
  26. J Alzheimers Dis. 2005 Feb;7(1):63-80 - PubMed
  27. J Med Chem. 2018 Sep 13;61(17):7630-7639 - PubMed
  28. J Biol Chem. 2012 Mar 16;287(12):9299-310 - PubMed
  29. Metabolism. 1980 May;29(5):488-94 - PubMed
  30. J Cell Biochem. 2017 Nov;118(11):3855-3865 - PubMed
  31. J Biomol Struct Dyn. 2019 Feb;37(2):321-335 - PubMed
  32. Curr Neuropharmacol. 2013 May;11(3):315-35 - PubMed
  33. Exp Gerontol. 2012 Nov;47(11):858-64 - PubMed
  34. Nat Clin Pract Neurol. 2006 Mar;2(3):159-66 - PubMed
  35. Oxid Med Cell Longev. 2017;2017:7303096 - PubMed
  36. Biotechnol Appl Biochem. 2016 Jan-Feb;63(1):145-50 - PubMed
  37. Neurosci Biobehav Rev. 2011 May;35(6):1397-409 - PubMed
  38. Prog Neurobiol. 2015 Jun;129:37-57 - PubMed
  39. Pharmacol Rep. 2016 Feb;68(1):127-38 - PubMed
  40. ACS Chem Neurosci. 2014 May 21;5(5):377-89 - PubMed
  41. Ann N Y Acad Sci. 1959 Mar 30;74(3):473-7 - PubMed
  42. Mol Pharm. 2018 Jun 4;15(6):2206-2223 - PubMed
  43. J Chem Phys. 2007 Jan 7;126(1):014101 - PubMed
  44. Altern Med Rev. 2009 Dec;14(4):373-9 - PubMed
  45. J Comput Chem. 2013 Sep 30;34(25):2135-45 - PubMed

Publication Types